Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Taku Yoshiya has a total of 216 co-authors. Here are the top co-authors by number of shared publications:

  • Shugo Tsuda

    Peptide Institute, Inc., Ibaraki, Osaka 567-0085, Japan.

    22 shared publications
  • Shun Masuda

    Peptide Institute, Inc. Osaka Japan

    12 shared publications
  • Tooru Kimura

    Department of Medicinal Chemistry, Division of Medicinal Chemical Sciences, Center for Frontier Research in Medicinal Science, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan

    11 shared publications
  • Youhei Sohma

    Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan

    10 shared publications
  • Masayoshi Mochizuki

    Peptide Institute Inc., 7-2-9 Saito-Asagi, Ibaraki-shi, Osaka, 567-0085, Japan

    9 shared publications
  • Yoshiaki Kiso

    Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan

    8 shared publications

Latest Publications

  • Open Access

    Discovery of a Novel γ‐Glutamylcyclotransferase Inhibitor Plumbagin by Luminescence‐Based High‐Throughput Screening

    by Keiko Taniguchi, Yukie Nohara, Mano Horinaka, Kozue Nose, Masaya Mori, Hiromi Ii, Hiroko Kawakami, Kazuto Yano, Susumu Nakata, Taku Yoshiya, et al.

    γ‐Glutamylcyclotransferase (GGCT) is a highly expressed protein in various cancers, and its knockdown and inhibitors suppress the growth of cancer cells in vitro and in vivo. Although GGCT is a promising target for anti‐cancer strategies, no drugs have progressed to clinical availability yet. We established a novel target‐based and cell‐based screening method for GGCT inhibitors, enabling the efficient discovery of compounds that inhibit intracellular GGCT activity. Using the chemiluminogenic probe LISA‐103 in response to GGCT enzymatic activity, high‐throughput screening for GGCT inhibitors was performed in lung cancer SW1573 cells. The hit compound plumbagin was identified as a novel GGCT inhibitor that suppressed its activity intracellularly. Plumbagin directly bound to a GGCT‐recombinant protein and inhibited its activity. Moreover, plumbagin up‐regulated p21, a cyclin‐dependent kinase inhibitor, and activated the tumor suppressor RB protein, inhibiting cell growth and cell cycle progression in breast MCF7 and colon HCT116 cancer cell lines. These phenomena induced by plumbagin mimicked the effect of GGCT depletion. The treatment with plumbagin suppressed tumor growth of HCT116 xenograft mice. These results suggest the potential of plumbagin in cancer therapy as a GGCT inhibitor.

  • Open Access

    Development of tCAP(N3): Affinity Peptide‐Aided, pH‐Triggered Strategy for Site‐Specific Native IgG Modification

    by Hiroko Kawakami, Abdur Rafique, Shugo Tsuda, Asaki Nagashima, Yukie Nohara, Naoki Dozono, Ken Sakamoto, Shun Masuda, Masato Kiyoshi, Hiroko Shibata, et al.

    Direct modification of native antibodies with affinity peptides remains a significant challenge, primarily because the affinity peptide often stays bound to the antibody and blocks its interaction with key receptors. In this study, we developed tCAP(N3), a novel traceless chemical conjugation method that employs an affinity peptide. tCAP(N3) can be stored for over a year at refrigerated temperature, as it contains an active ester precursor that can be spontaneously activated under neutral conditions. When tCAP(N3) was mixed with a target native IgG, Ac‐Lys(N 3 )‐Gly‐Gly was site‐selectively transferred onto Lys248, yielding divalently azidated IgG that can be further modified with DBCO compounds. The resulting antibody conjugates retained Fc receptor binding and antigen recognition comparable to the parent IgG.


  • Open Access

    Cyclic homodimer formation by singlet oxygen-mediated oxidation of carnosine

    by Hiroko Kawakami, Yuki Itakura, Tetsuya Yamamoto, Taku Yoshiya

    Although carnosine (β-Ala-L-His) is one of physiological protectants against in vivo damages caused by reactive oxygen species (ROS), its reactivity against singlet oxygen (1O2), an ROS, is still unclear at the molecular level. Theoretically, the reaction consists of two steps: i) oxygenation of the His side chain to form an electrophilic endoperoxide and ii) nucleophilic addition to the endoperoxide. In this study, the end product of 1O2-mediated carnosine oxidation was evaluated using 2D-NMR and other analytical methods both in the presence and absence of external nucleophiles. Interestingly, as the end product without external nucleophile, a cyclic homodimer was confirmed under our particular conditions. The reaction was also replicated in pork specimens.


  • Open Access

    Synthesis of the full-length hepatitis B virus core protein and its capsid formation

    by Keisuke Aoki, Shugo Tsuda, Naoko Ogata, Michiyo Kataoka, Jumpei Sasaki, Shinsuke Inuki, Hiroaki Ohno, Koichi Watashi, Taku Yoshiya, Shinya Oishi

    Protocols for chemical synthesis and in vitro assembly of the hepatitis B virus full-length core protein (Cp183) were investigated.


  • Development of an activity-based chemiluminogenic probe for γ-glutamylcyclotransferase

    by Yukie Nohara, Keiko Taniguchi, Hiromi Ii, Shun Masuda, Hiroko Kawakami, Masakatsu Matsumoto, Yasunao Hattori, Susumu Kageyama, Toshiyuki Sakai, Susumu Nakata, et al.

    While γ-glutamylcyclotransferase (GGCT) has been implicated in cancer-cell proliferation, the role of GGCT enzymatic activity in the regulation of cancer-cell growth remains unclear. Toward further understanding of GGCT in vivo, here we report a novel cell-permeable chemiluminogenic probe “MAM-LISA-103” that detects intracellular GGCT activity and apply it to in vivo imaging. We first developed a chemiluminogenic probe LISA-103, which simply and sensitively detects the enzymatic activity of recombinant GGCT through chemiluminescence. We then designed the cell-permeable GGCT probe MAM-LISA-103 and applied it to several biological experiments. MAM-LISA-103 successfully detected the intracellular GGCT activity in GGCT-overexpressing NIH-3T3 cells. Moreover, MAM-LISA-103 demonstrated tumor-imaging ability when administered to a xenograft model using immunocompromised mice inoculated with MCF7 cells.


  • Open Access

    Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine

    by Ayaka Aso, Hinako Nabetani, Yoshifumi Matsuura, Yuichiro Kadonaga, Yoshifumi Shirakami, Tadashi Watabe, Taku Yoshiya, Masayoshi Mochizuki, Kazuhiro Ooe, Atsuko Kawakami, et al.

    Fibroblast activation proteins (FAP) are overexpressed in the tumor stroma and have received attention as target molecules for radionuclide therapy. The FAP inhibitor (FAPI) is used as a probe to deliver nuclides to cancer tissues. In this study, we designed and synthesized four novel 211At-FAPI(s) possessing polyethylene glycol (PEG) linkers between the FAP-targeting and 211At-attaching moieties. 211At-FAPI(s) and piperazine (PIP) linker FAPI exhibited distinct FAP selectivity and uptake in FAPII-overexpressing HEK293 cells and the lung cancer cell line A549. The complexity of the PEG linker did not significantly affect selectivity. The efficiencies of both linkers were almost the same. Comparing the two nuclides, 211At was superior to 131I in tumor accumulation. In the mouse model, the antitumor effects of the PEG and PIP linkers were almost the same. Most of the currently synthesized FAPI(s) contain PIP linkers; however, in our study, we found that PEG linkers exhibit equivalent performance. If the PIP linker is inconvenient, a PEG linker is expected to be an alternative.


  • Dioxetane Derivative Containing Carboxy Group as a Chemiluminophore‐Introducing Reagent

    by Yukie Nohara, Shun Masuda, Kazuko Kaneda‐Nakashima, Yoshifumi Shirakami, Masakatsu Matsumoto, Taku Yoshiya

    Some types of dioxetanes are called chemiluminophores because they produce luminescence light without the use of enzymes. Here, we designed and synthesized a novel carboxy group‐containing chemiluminophore derivative, which enabled the simple introduction of such a chemiluminophore to the molecule of interest. Furthermore, we demonstrate that the in vivo imaging system (IVIS imaging system) can recognize tagged chemicals, indicating that such a chemiluminophore could be employed as a tracer molecule for biological studies.


  • Open Access

    Preparation of Monoclonal Antibodies Specifically Reacting with the Trichothecene Mycotoxins Nivalenol and 15-Acetylnivalenol via the Introduction of a Linker Molecule into Its C-15 Position

    by Kyoko Noda, Yuki Hirakawa, Tomomi Nishino, Ritsuto Sekizuka, Marin Kishimoto, Tomohiro Furukawa, Sakiko Sawane, Ayu Matsunaga, Naoki Kobayashi, Kazutoshi Sugita, et al.

    Nivalenol (NIV) is a trichothecene mycotoxin that is more toxic than deoxynivalenol. It accumulates in grains due to infection with Fusarium species, which are the causative agents of scab or Fusarium head blight. An immunoassay, which is a rapid and easy analytical method, is necessary for monitoring NIV in grains. However, a specific antibody against NIV has not been prepared previously. To establish an immunoassay, we prepared NIV, introduced a linker, and generated antibodies against it. NIV was prepared from a culture of Fusarium kyushuense obtained from pressed barley through chromatographic procedures with synthetic adsorbents and silica gel. NIV was reacted with glutaric anhydride, and the reaction was stopped before mono-hemiglutaryl-NIV was changed to di-hemiglutaryl-NIV. 15-O-Hemiglutaryl-NIV was isolated via preparative HPLC and bound to keyhole limpet hemocyanin (KLH) using the active ester method. Two different monoclonal antibodies were prepared by immunizing mice with the NIV-KLH conjugate. The 50% inhibitory concentration values were 36 and 37 ng/mL. These antibodies also showed high reactivity in a direct competitive enzyme-linked immunosorbent assay and specifically reacted with NIV and 15-acetyl-NIV but not with deoxynivalenol and 4-acetyl-NIV.


  • Open Access

    Intermolecular Interactions between a Membrane Protein and a Glycolipid Essential for Membrane Protein Integration

    by Shoko Mori, Kaoru Nomura, Kohki Fujikawa, Tsukiho Osawa, Masafumi Shionyu, Takao Yoda, Tsuyoshi Shirai, Shugo Tsuda, Kumiko Yoshizawa-Kumagaye, Shun Masuda, et al.

    Inducing newly synthesized proteins to appropriate locations is an indispensable biological function in every organism. Integration of proteins into biomembranes in Escherichia coli is mediated by proteinaceous factors, such as Sec translocons and an insertase YidC. Additionally, a glycolipid named MPIase (membrane protein integrase), composed of a long sugar chain and pyrophospholipid, was proven essential for membrane protein integration. We reported that a synthesized minimal unit of MPIase possessing only one trisaccharide, mini-MPIase-3, involves an essential structure for the integration activity. Here, to elucidate integration mechanisms using MPIase, we analyzed intermolecular interactions of MPIase or its synthetic analogs with a model substrate, the Pf3 coat protein, using physicochemical methods. Surface plasmon resonance (SPR) analyses revealed the importance of a pyrophosphate for affinity to the Pf3 coat protein. Compared with mini-MPIase-3, natural MPIase showed faster association and dissociation due to its long sugar chain despite the slight difference in affinity. To focus on more detailed MPIase substructures, we performed docking simulations and saturation transfer difference-nuclear magnetic resonance. These experiments yielded that the 6-O-acetyl group on glucosamine and the phosphate of MPIase play important roles leading to interactions with the Pf3 coat protein. The high affinity of MPIase to the hydrophobic region and the basic amino acid residues of the protein was suggested by docking simulations and proven experimentally by SPR using protein mutants devoid of target regions. These results demonstrated the direct interactions of MPIase with a substrate protein and revealed detailed mechanisms of membrane protein integration.


  • Identification of U83836E as a γ-glutamylcyclotransferase inhibitor that suppresses MCF7 breast cancer xenograft growth

    by Hiromi Ii, Yukie Nohara, Taku Yoshiya, Shun Masuda, Shugo Tsuda, Shinya Oishi, Jonathan Friedman, Takumi Kawabe, Susumu Nakata